{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:50:07Z","timestamp":1768877407500,"version":"3.49.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T00:00:00Z","timestamp":1233619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1038\/ncponc1323","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T14:56:29Z","timestamp":1233672989000},"page":"163-174","source":"Crossref","is-referenced-by-count":102,"title":["Effect of bisphosphonates on pain and quality of life in patients with bone metastases"],"prefix":"10.1038","volume":"6","author":[{"given":"Luis","family":"Costa","sequence":"first","affiliation":[]},{"given":"Pierre P","family":"Major","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,2,3]]},"reference":[{"key":"BFncponc1323_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-006-0005-9","volume":"8","author":"C Van Poznak","year":"2006","unstructured":"Van Poznak C and Nadal C (2006) Bone integrity and bone metastases in breast cancer. Curr Oncol Rep 8: 22\u201328","journal-title":"Curr Oncol Rep"},{"key":"BFncponc1323_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.hoc.2006.03.011","volume":"20","author":"F Saad","year":"2006","unstructured":"Saad F (2006) Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 20: 947\u2013963","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 4","key":"BFncponc1323_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9 (Suppl 4): 14\u201327","journal-title":"Oncologist"},{"key":"BFncponc1323_CR4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00015458.1998.12098427","volume":"98","author":"I Fourneau","year":"1998","unstructured":"Fourneau I and Broos P (1998) Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir Belg 98: 255\u2013260","journal-title":"Acta Chir Belg"},{"key":"BFncponc1323_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3322\/canjclin.55.2.109","volume":"55","author":"G Deng","year":"2005","unstructured":"Deng G and Cassileth BR (2005) Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance. CA Cancer J Clin 55: 109\u2013116","journal-title":"CA Cancer J Clin"},{"key":"BFncponc1323_CR6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/0470869127.ch16","volume":"261","author":"PW Mantyh","year":"2004","unstructured":"Mantyh PW (2004) A mechanism-based understanding of bone cancer pain. Novartis Found Symp 261: 194\u2013214 discussion 214\u2013219, 256\u2013261","journal-title":"Novartis Found Symp"},{"key":"BFncponc1323_CR7","first-page":"65","volume":"45","author":"C Ripamonti","year":"2001","unstructured":"Ripamonti C and Fulfaro F (2001) Pathogenesis and pharmacological treatment of bone pain in skeletal metastases. QJ Nucl Med 45: 65\u201377","journal-title":"QJ Nucl Med"},{"key":"BFncponc1323_CR8","first-page":"15","volume":"3","author":"MA Sabino","year":"2005","unstructured":"Sabino MA and Mantyh PW (2005) Pathophysiology of bone cancer pain. J Support Oncol 3: 15\u201324","journal-title":"J Support Oncol"},{"issue":"Suppl","key":"BFncponc1323_CR9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80 (Suppl): 1588\u20131594","journal-title":"Cancer"},{"key":"BFncponc1323_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP et al. (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16: 579\u2013584","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"BFncponc1323_CR11","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","volume":"11","author":"N Kinnane","year":"2007","unstructured":"Kinnane N (2007) Burden of bone disease. Eur J Oncol Nurs 11 (Suppl 2): S28\u2013S31","journal-title":"Eur J Oncol Nurs"},{"key":"BFncponc1323_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1188\/03.CJON.641-646","volume":"7","author":"CD Reich","year":"2003","unstructured":"Reich CD (2003) Advances in the treatment of bone metastases. Clin J Oncol Nurs 7: 641\u2013646","journal-title":"Clin J Oncol Nurs"},{"key":"BFncponc1323_CR13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00520-007-0244-9","volume":"15","author":"IJ Diel","year":"2007","unstructured":"Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15: 1243\u20131249","journal-title":"Support Care Cancer"},{"key":"BFncponc1323_CR14","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS and Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129\u2013138","journal-title":"Ann Acad Med Singapore"},{"key":"BFncponc1323_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11: 570\u2013579","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","volume":"34","author":"WO Spitzer","year":"1981","unstructured":"Spitzer WO et al. (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34: 585\u2013597","journal-title":"J Chronic Dis"},{"key":"BFncponc1323_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK et al. (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1323_CR18","doi-asserted-by":"crossref","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16: 199\u2013208","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"BFncponc1323_CR19","first-page":"15","volume":"9","author":"E Adrover","year":"2005","unstructured":"Adrover E et al. (2005) Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL). J Outcomes Res 9: 15\u201327","journal-title":"J Outcomes Res"},{"key":"BFncponc1323_CR20","unstructured":"Harris K and Chow E (online 2006) Bone metastases module [ http:\/\/groups.eortc.be\/qol\/downloads\/2006_southampton\/\u00a0chow_bone_mets_module_short_nov2006.pdf ] (accessed 15 December 2008)"},{"key":"BFncponc1323_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3111\/200710027039","volume":"10","author":"A Sureda","year":"2007","unstructured":"Sureda A et al. (2007) Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. J Med Econ 10: 27\u201339","journal-title":"J Med Econ"},{"key":"BFncponc1323_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11864-005-0023-0","volume":"6","author":"A Lipton","year":"2005","unstructured":"Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6: 161\u2013171","journal-title":"Curr Treat Options Oncol"},{"key":"BFncponc1323_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735\u20131744","journal-title":"Cancer"},{"key":"BFncponc1323_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1323_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1345\/aph.1E357","volume":"39","author":"AA Licata","year":"2005","unstructured":"Licata AA (2005) Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39: 668\u2013677","journal-title":"Ann Pharmacother"},{"key":"BFncponc1323_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP et al. (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126\u20131134","journal-title":"Br J Cancer"},{"key":"BFncponc1323_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1677\/erc.1.01094","volume":"13","author":"M Caraglia","year":"2006","unstructured":"Caraglia M et al. (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13: 7\u201326","journal-title":"Endocr Relat Cancer"},{"key":"BFncponc1323_CR28","first-page":"3890","volume":"57","author":"S Boissier","year":"1997","unstructured":"Boissier S et al. (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57: 3890\u20133894","journal-title":"Cancer Res"},{"key":"BFncponc1323_CR29","unstructured":"Berger W et al. (2006) The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation [abstract #4981]. Proc Am Assoc Cancer Res 46"},{"key":"BFncponc1323_CR30","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P et al. (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538\u20136544","journal-title":"Cancer Res"},{"key":"BFncponc1323_CR31","first-page":"221","volume":"8","author":"F Saad","year":"2006","unstructured":"Saad F (2006) The role of bisphosphonates in the management of prostate cancer. Curr Oncol Rep 8: 221\u2013227","journal-title":"Rep"},{"key":"BFncponc1323_CR32","volume-title":"Cochrane Database of Systematic Reviews","author":"N Pavlakis","year":"2005","unstructured":"Pavlakis N et al. (2005) Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003474. 10.1002\/14651858.CD003474.pub2."},{"key":"BFncponc1323_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17453670610046361","volume":"77","author":"N Hansen-Algenstaedt","year":"2006","unstructured":"Hansen-Algenstaedt N et al. (2006) Sequential changes in vessel formation and micro-vascular function during bone repair. Acta Orthop 77: 429\u2013439","journal-title":"Acta Orthop"},{"key":"BFncponc1323_CR34","first-page":"1109","volume":"12","author":"U Vogt","year":"2004","unstructured":"Vogt U et al. (2004) Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5-fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12: 1109\u20131114","journal-title":"Oncol Rep"},{"key":"BFncponc1323_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000093006","volume":"70","author":"DR Budman","year":"2006","unstructured":"Budman DR and Calabro A (2006) Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70: 147\u2013153","journal-title":"Oncology"},{"key":"BFncponc1323_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.cellbi.2007.02.004","volume":"31","author":"OH Ozturk","year":"2007","unstructured":"Ozturk OH et al. (2007) Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 31: 1069\u20131071","journal-title":"Cell Biol Int"},{"key":"BFncponc1323_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00280-005-0025-4","volume":"57","author":"G Bertelli","year":"2006","unstructured":"Bertelli G et al. (2006) Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 57: 46\u201351","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFncponc1323_CR38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ijc.20602","volume":"113","author":"HL Neville-Webbe","year":"2005","unstructured":"Neville-Webbe HL et al. (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364\u2013371","journal-title":"Int J Cancer"},{"key":"BFncponc1323_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/02841860510029617","volume":"44","author":"A Ull\u00e9n","year":"2005","unstructured":"Ull\u00e9n A et al. (2005) Additive\/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 44: 644\u2013650","journal-title":"Acta Oncol"},{"key":"BFncponc1323_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC et al. (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453\u2013475","journal-title":"Cancer Treat Rev"},{"key":"BFncponc1323_CR41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.36076\/ppj.2007\/10\/479","volume":"10","author":"JC Ballantyne","year":"2007","unstructured":"Ballantyne JC (2007) Opioid analgesia: perspectives on right use and utility. Pain Physician 10: 479\u2013491","journal-title":"Pain Physician"},{"key":"BFncponc1323_CR42","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","volume":"61","author":"SJ Panchal","year":"2007","unstructured":"Panchal SJ et al. (2007) Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 61: 1181\u20131187","journal-title":"Int J Clin Pract"},{"key":"BFncponc1323_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/canjclin.57.4.225","volume":"57","author":"RD Loberg","year":"2007","unstructured":"Loberg RD et al. (2007) The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 57: 225\u2013241","journal-title":"CA Cancer J Clin"},{"key":"BFncponc1323_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0304-3959(01)00324-4","volume":"93","author":"T Meuser","year":"2001","unstructured":"Meuser T et al. (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93: 247\u2013257","journal-title":"Pain"},{"key":"BFncponc1323_CR45","first-page":"641","volume":"16","author":"K Yoshida","year":"2006","unstructured":"Yoshida K and Hiratsuka J (2006) Palliative radiotherapy for metastatic bone tumor [Japanese]. Clin Calcium 16: 641\u2013645","journal-title":"Clin Calcium"},{"key":"BFncponc1323_CR46","doi-asserted-by":"crossref","unstructured":"Fairchild A et al. (2008) The rapid access palliative radiotherapy program: blueprint for initiation of a one-stop multidisciplinary bone metastases clinic. Support Care Cancer [10.1007\/s00520-008-0468-3]","DOI":"10.1007\/s00520-008-0468-3"},{"key":"BFncponc1323_CR47","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0360-3016(03)00274-8","volume":"56","author":"S Smeland","year":"2003","unstructured":"Smeland S et al. (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56: 1397\u20131404","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFncponc1323_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.radonc.2004.12.016","volume":"75","author":"E Chow","year":"2005","unstructured":"Chow E et al. (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol 75: 64\u201369","journal-title":"Radiother Oncol"},{"key":"BFncponc1323_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/jpm.1998.1.277","volume":"1","author":"RS Hellman","year":"1998","unstructured":"Hellman RS and Krasnow AZ (1998) Radionuclide therapy for palliation of pain due to osteoblastic metastases. J Palliat Med 1: 277\u2013283","journal-title":"J Palliat Med"},{"issue":"Suppl 1","key":"BFncponc1323_CR50","first-page":"38S","volume":"46","author":"VJ Lewington","year":"2005","unstructured":"Lewington VJ (2005) Bone-seeking radionuclides for therapy. J Nucl Med 46 (Suppl 1): 38S\u201347S","journal-title":"J Nucl Med"},{"key":"BFncponc1323_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000082923","volume":"67","author":"T Delea","year":"2004","unstructured":"Delea T et al. (2004) The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67: 390\u2013396","journal-title":"Oncology"},{"issue":"Suppl 4","key":"BFncponc1323_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9 (Suppl 4): 3\u201313","journal-title":"Oncologist"},{"key":"BFncponc1323_CR53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s007740200033","volume":"20","author":"J Iwamoto","year":"2002","unstructured":"Iwamoto J et al. (2002) Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 20: 228\u2013234","journal-title":"J Bone Miner Metab"},{"key":"BFncponc1323_CR54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","volume":"165","author":"A Heidenreich","year":"2001","unstructured":"Heidenreich A et al. (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136\u2013140","journal-title":"J Urol"},{"key":"BFncponc1323_CR55","first-page":"701","volume":"88","author":"M Tubiana-Hulin","year":"2001","unstructured":"Tubiana-Hulin M et al. (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [French]. Bull Cancer 88: 701\u2013707","journal-title":"Bull Cancer"},{"key":"BFncponc1323_CR56","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","volume":"21","author":"DS Ernst","year":"2003","unstructured":"Ernst DS et al. (2003) Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335\u20133342","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.archger.2005.10.006","volume":"43","author":"A Santangelo","year":"2006","unstructured":"Santangelo A et al. (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43: 187\u2013192","journal-title":"Arch Gerontol Geriatr"},{"key":"BFncponc1323_CR58","first-page":"49","volume":"17","author":"E Ozyuvaci","year":"2005","unstructured":"Ozyuvaci E et al. (2005) The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer [Turkish]. Agri 17: 49\u201353","journal-title":"Agri"},{"issue":"Suppl 2","key":"BFncponc1323_CR59","first-page":"ii278","volume":"16","author":"DA Donat","year":"2005","unstructured":"Donat DA et al. (2005) Low-dose clodronate as adjunctive therapy in breast cancer patients with bone metastases [abstract #27P]. Ann Oncol 16 (Suppl 2): ii278","journal-title":"Ann Oncol"},{"key":"BFncponc1323_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.pcan.4500752","volume":"7","author":"P Rodrigues","year":"2004","unstructured":"Rodrigues P et al. (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7: 350\u2013354","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFncponc1323_CR61","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1590\/S1677-55382003000300006","volume":"29","author":"F Hering","year":"2003","unstructured":"Hering F et al. (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29: 228\u2013233","journal-title":"Int Braz J Urol"},{"key":"BFncponc1323_CR62","first-page":"4717","volume":"17","author":"P Strang","year":"1997","unstructured":"Strang P et al. (1997) The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 17: 4717\u20134721","journal-title":"Anticancer Res"},{"key":"BFncponc1323_CR63","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785\u20131791","journal-title":"N Engl J Med"},{"key":"BFncponc1323_CR64","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN et al. (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038\u20132044","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR65","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL et al. (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846\u2013854","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR66","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21","author":"EJ Small","year":"2003","unstructured":"Small EJ et al. (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21: 4277\u20134284","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"BFncponc1323_CR67","first-page":"77","volume":"22","author":"R Wong","year":"2003","unstructured":"Wong R et al. (2003) A randomized double blind placebo controlled trial of radiotherapy (XRT) with or without single dose pamidronate (PAM) for pain relief in patients with painful bone metastases [abstract #3099]. Proc Am Soc Clin Oncol 22 (Suppl): 77","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc1323_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1191\/026921601678320287","volume":"15","author":"L Groff","year":"2001","unstructured":"Groff L et al. (2001) The role of disodium pamidronate in the management of bone pain due to malignancy. Palliat Med 15: 297\u2013307","journal-title":"Palliat Med"},{"key":"BFncponc1323_CR69","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1054\/bjoc.2001.1832","volume":"84","author":"G Vitale","year":"2001","unstructured":"Vitale G et al. (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84: 1586\u20131590","journal-title":"Br J Cancer"},{"key":"BFncponc1323_CR70","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body JJ et al. (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111: 306\u2013312","journal-title":"Pain"},{"key":"BFncponc1323_CR71","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399\u20131405","journal-title":"Ann Oncol"},{"key":"BFncponc1323_CR72","first-page":"113","volume":"3","author":"D Tripathy","year":"2005","unstructured":"Tripathy D and Bergstr\u00f6m B (2005) Effect of intravenous and oral ibandronate on the need for analgesic interventions for metastatic bone pain: phase III trial results [abstract #404]. Eur J Cancer Suppl 3: 113","journal-title":"Eur J Cancer Suppl"},{"key":"BFncponc1323_CR73","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD et al. (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353\u20132359","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR74","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/annonc\/mdh173","volume":"15","author":"D Tripathy","year":"2004","unstructured":"Tripathy D et al. (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15: 743\u2013750","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"BFncponc1323_CR75","first-page":"ii277","volume":"16","author":"JJ Body","year":"2005","unstructured":"Body JJ et al. (2005) Acute and long-term relief from metastatic bone pain with intravenous ibandronate: phase III and phase II trial results [abstract #26P]. Ann Oncol 16 (Suppl 2): ii277","journal-title":"Ann Oncol"},{"key":"BFncponc1323_CR76","unstructured":"Heidenreich A et al. (2005) Ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer [poster #279]. Presented at the 2005 ASCO Prostate Cancer Symposium: 2005 February 17\u201319, Orlando, FL"},{"key":"BFncponc1323_CR77","first-page":"467","volume":"13","author":"V Vassiliou","year":"2005","unstructured":"Vassiliou V et al. (2005) Combination of radiotherapy and ibandronate for the treatment of bone metastases: clinical evaluation and radiological assessment [abstract 21-160]. Support Care Cancer 13: 467","journal-title":"Support Care Cancer"},{"key":"BFncponc1323_CR78","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","volume":"22","author":"I Mancini","year":"2004","unstructured":"Mancini I et al. (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22: 3587\u20133592","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR79","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082\u20131090","journal-title":"Cancer"},{"key":"BFncponc1323_CR80","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90: 1133\u20131137","journal-title":"Br J Cancer"},{"key":"BFncponc1323_CR81","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL et al. (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9: 687\u2013695","journal-title":"Oncologist"},{"key":"BFncponc1323_CR82","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N et al. (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23: 3314\u20133321","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR83","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F et al. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc1323_CR84","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/annonc\/mdl041","volume":"17","author":"KP Weinfurt","year":"2006","unstructured":"Weinfurt KP et al. (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17: 986\u2013989","journal-title":"Ann Oncol"},{"key":"BFncponc1323_CR85","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS et al. (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150\u20133157","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR86","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100: 2613\u20132621","journal-title":"Cancer"},{"key":"BFncponc1323_CR87","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377\u2013387","journal-title":"Cancer J"},{"key":"BFncponc1323_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS et al. (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100: 36\u201343","journal-title":"Cancer"},{"key":"BFncponc1323_CR89","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A et al. (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92: 1869\u20131876","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"BFncponc1323_CR90","first-page":"734s","volume":"23","author":"W Wiktor-Jedrzejczak","year":"2005","unstructured":"Wiktor-Jedrzejczak W (2005) Reduction of pain as the primary determinant of improved quality of life of cancer patients receiving zoledronic acid (Zol) for bone involvement [abstract #8022]. J Clin Oncol 23 (Suppl): 734s","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR91","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00520-006-0211-x","volume":"15","author":"C Ripamonti","year":"2007","unstructured":"Ripamonti C et al. (2007) Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Support Care Cancer 15: 1117\u20131184","journal-title":"Support Care Cancer"},{"key":"BFncponc1323_CR92","unstructured":"Stanculeanu DL et al. (2006) Zoledronic acid treatment in osteocondensant bone metastasis prostate cancer patients [poster #289]. Presented at the 2006 ASCO Prostate Cancer Symposium: 2006 February 24\u201326, San Francisco, CA"},{"key":"BFncponc1323_CR93","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2004.08.041","volume":"65","author":"E Efstathiou","year":"2005","unstructured":"Efstathiou E et al. (2005) Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65: 126\u2013130","journal-title":"Urology"},{"key":"BFncponc1323_CR94","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","volume":"24","author":"MJ Clemons","year":"2006","unstructured":"Clemons MJ et al. (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24: 4895\u20134900","journal-title":"J Clin Oncol"},{"key":"BFncponc1323_CR95","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","volume":"17","author":"F Fulfaro","year":"2005","unstructured":"Fulfaro F et al. (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17: 555\u2013559","journal-title":"J Chemother"},{"issue":"14_suppl","key":"BFncponc1323_CR96","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1200\/jco.2004.22.14_suppl.8058","volume":"22","author":"P. P. Major","year":"2004","unstructured":"Major PP et al. (2004) Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: a survival-adjusted cumulative incidence analysis [poster #8058]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology: 2004 June 5\u20138, New Orleans, LA","journal-title":"Journal of Clinical Oncology"},{"key":"BFncponc1323_CR97","unstructured":"Saad F et al. (2003) Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone [poster #1473]. Presented at the American Urological Association Annual Meeting: 2003 April 26\u2013May 1, Chicago, IL"},{"key":"BFncponc1323_CR98","first-page":"S62","volume":"100","author":"L Costa","year":"2006","unstructured":"Costa L and Chen YM (2006) Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate [abstract #1071]. Breast Cancer Res Treat 100: S62","journal-title":"Breast Cancer Res Treat"},{"key":"BFncponc1323_CR99","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","volume":"6","author":"V Hirsh","year":"2004","unstructured":"Hirsh V et al. (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6: 170\u2013174","journal-title":"Clin Lung Cancer"},{"key":"BFncponc1323_CR100","unstructured":"Rosen L et al. Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small lung cancer (NSCLC) and bone metastases [poster #73]. Presented at the What is New in Bisphosphonates? Seventh Workshop on Bisphosphonates\u2014From the Laboratory to the Patient: 2004 March 24\u201326, Davos, Switzerland"},{"issue":"Suppl 4","key":"BFncponc1323_CR101","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1569-9056(05)80576-7","volume":"3","author":"F Saad","year":"2005","unstructured":"Saad F et al. (2005) Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases [abstract #572]. Eur Urol 3 (Suppl 4): 145","journal-title":"Eur Urol"},{"key":"BFncponc1323_CR102","doi-asserted-by":"crossref","unstructured":"Saad F et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster #1472]. Presented at the American Urological Association Annual Meeting: 2003 April 26\u2013May 1, Chicago, IL","DOI":"10.3816\/CGC.2002.n.016"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T23:25:53Z","timestamp":1710026753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,3]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["BFncponc1323"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1323","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,3]]}}}